Head-to-head evidence
albuterol HFA (Proventil HFA) vs Olodaterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol HFA (Proventil HFA)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00635505 · Phase 3 · terminated
In this trial, Proventil-HFA is the established reference product that the investigational Armstrong's albuterol-HFA is being compared against, rather than the agent under primary evaluation itself, and no results have been posted yet.
Olodaterol
Marketed by Boehringer Ingelheim
NCT00467740 · Phase 2 · completed
The study randomized 296 participants to placebo or one of four olodaterol doses, but the registry does not clearly report whether treatment assignment was blinded. Its primary outcome was a lung-function surrogate rather than a hard clinical outcome, and results were mixed across doses: only olodaterol 20 micrograms significantly improved trough FEV1 versus placebo at 4 weeks.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol HFA (Proventil HFA)'s landscape · Olodaterol's landscape